



Attorney Docket P1071P1D15

PATENT



EL 599 585 012 US: Express Mail Number

Please type a plus sign (+) inside this box +

November 28, 2000: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C.

Pamela Gavette

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**BOX PATENT APPLICATION Assistant Commissioner of Patents** Washington, D.C. 20231

## NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Ross G. Clark, Auckland, New Zealand Henry B. Lowman, El Granada, California lain C.A.F. Robinson, Hertfordshire, Great Britain

**INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES** Title:

- 1. Type of Application
- [] This application is for an original, non-provisional application.
- [] This is a non-provisional application claiming priority to provisional application no. \_ , filed \_\_\_\_, the entire disclosure of which is hereby incorporated by reference.
- [ ] continuation-in-part [ ] continuation [ x ] divisional application [ x ] claiming priority to application Serial Number 09/052,888, filed March 31, 1998, which is a continuation-in-part to application no. 08/825,852, filed on April 4, 1997 the entire disclosure of which is hereby incorporated by reference.
- Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) 2. (Non-provisional)
  - 150 pages of specification
  - pages of claims
  - page(s) of abstract
  - sheet(s) of drawings
    - [x] formal [] informal
  - 40 pages of sequence listing

Ü

|   | 3. | Declaration or Oath   |  |  |  |  |
|---|----|---|--|--|--|--|
| The Text of H II I |    | (for new and CIP applications; also for Cont./Div. where inventor(s) are being added)  An executed declaration of the inventor(s) [] is enclosed [] will follow.  |  |  |  |  |
|   |    | (for Cont./Div. where inventorship is the same or inventor(s) being deleted)  X A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).  |  |  |  |  |
|   |    | (for Cont./Div. where inventor(s) being deleted)  A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).   |  |  |  |  |
|   | 4. | Assignment  |  |  |  |  |
|   |    | (for new and CIP applications)  An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.   |  |  |  |  |
|   |    | (for cont./div.)x_ The prior application is assigned of record to Genentech, Inc.   |  |  |  |  |
|   | 5. | Amendments (for continuation and divisional applications)   |  |  |  |  |
|   |    | Cancel in this application original claims _ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)  |  |  |  |  |
| Control Control Trans                               |    | A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)  |  |  |  |  |
|   |    | Relate Back 35 U.S.C. 120 or 35 U.S.C. 119  |  |  |  |  |
|   |    | X Amend the specification by deleting the first sentence and replacing it with:   |  |  |  |  |
| QI  |    | This is a   |  |  |  |  |
|   |    | non-provisional application continuation divisional continuation-in-part  |  |  |  |  |
|   |    | of co-pending application(s)  |  |  |  |  |
|   |    | x Serial No. 09/052,888 filed on March 31, 1998, which claims priority to application no. 08/825,852, filed on April 4, 1997, which issued as U.S. Pat. No. 6,121,416, which applications are incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120, |  |  |  |  |
|   |    | International Application _ filed on _ which designated the U.S., which application(s) is(are)  |  |  |  |  |

incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--

provisional application No. \_ filed \_\_, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

## 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

| CLAIMS FOR FEE CALCULATION                    |          |              |      |           |                             |  |  |
|---|----------|--------------|------|-----------|-----------------------------|--|--|
| Number Filed                                  |          | Number Extra |      | Rate      | Basic Fee<br>37 CFR 1.16(a) |  |  |
|   |          |              | 1.44 |           | \$710.00                    |  |  |
| Total<br>Claims                               | 2        | - 20 =       | 0    | X \$18.00 | \$0.00                      |  |  |
| Independent<br>Claims                         | 1        | - 3=         | 0    | X \$80.00 | \$0.00                      |  |  |
| Multiple dependent claim(s), if any + \$270.0 |          |              |      |           | \$0.00                      |  |  |
|   | \$710.00 |              |      |           |                             |  |  |

### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00. A duplicate copy of this transmittal is enclosed.

#### 8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.** 

# 9. Additional Papers Enclosed

- [] Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- [x] Letter and Request to Use Computer Readable Sequence.
- A new Power of Attorney or authorization of agent.
- [] Other:

# 10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

| <br>A petition, fee and/or response has been filed to extend the term in         |
|--|
| the pending prior application until  |
| <br>A copy of the petition for extension of time in the <i>prior</i> application |
| is attached  |

# 11. Correspondence Address:

X Address all future communications to:

Attn: Janet E. Hasak

Respectfully submitted, GENENTECH, INC.

Date: November 28, 2000

y: <u>Janet E. Hasak</u>

Reg. No. 28,616 Telephone No. (650) 225-1896

09157

PATENT TRADEMARK OFFICE

(3